Zakroczym, 10 June 2025 r.

**MARKET INSIGHT FORM**

**Purpose of the form:**

In connection with the implementation of the project titled ***"Development of a new combination medicinal product for the treatment of type 2 diabetes,"*** co-financed from the state budget under competitions organized by the Medical Research Agency, **we kindly request that you provide the estimated value of the planned procurement described in detail below under item II, as well as the information specified in Appendix no 1 to this market research form.**

**Please sign this Market Insight Form and send a scan (in the pdf format) by e-mail to: zapytaniaofertowe@lekam.pl by: 18 June 2025.**

If you need additional information, please contact us by e-mail: zapytaniaofertowe@lekam.pl

1. **Order specification:**
2. The planned order concerns the delivery *of* ***1,450 kg of the active substance Metformin Hydrochloride****, as described in detail in the specification in Section II.7 of this market research form*.
3. The ordering party reserves that the indicated quantity is estimated as necessary to carry out the research and does not anticipate partial orders or deliveries.
4. CPV CODE: 24000000-4 Chemical products
5. Delivery deadline: up to **3 months from the date of placing the order.**
6. Offer validity period: 60 days.
7. Place of completion of the order:

Przedsiębiorstwo Farmaceutyczne LEK-AM sp. z o.o., Zakroczym

1. Detailed order specification:

|  |  |
| --- | --- |
| **Lp.** | **Requirements** |
| **1.** | **Specification** |
| **1.1** | **Raw material name: Metformin Hydrochloride** Planned quantity to be purchased: 1,450 kg. Weight deviations are acceptable depending on the packaging used by the supplier.1. Pharmaceutical-grade substance, compliant with the requirements for raw materials used in solid oral dosage forms, holding a current Certificate of Suitability to the European Pharmacopoeia (CEP). 2. Particle size distribution conforming requirements: D(0.9) not more than 150 µm3. Polymorphic form: Form A 4. Retest period for micronized active substance: minimum 3 years, supported by stability test results. |
| **2.** | **Documentation** |
| **2.1** | Before delivery, the Contractor is obliged to provide the Ordering Party with the following documents for approval: 1. Certificate of analysis compliant with ICH Q6A specification requirements2. PSD histogram3. Confirmation of polymorphic form identity4. MSDS;5. Declaration of batch size6. Declaration that tests listed in the CoA were performed using validated methods and in accordance with Ph. Eur. (for general requirements) and with the specification outlined in the current EU ASMF version 7. Declaration that the offered batch of active substance was produced and micronized using a validated process under GMP conditions |
| **3.** | **Additional requirements** |
| **3.1** | Transport conditions:• in accordance with ASMF requirements, shipment under controlled conditions |
| **3.2** | In order for the offer to be considered, the Bidder must have deliver together with the offer, created in accordance with the Information Template constituting by appendix No. 1 to the Market Research Form following documents or declare in this form that the documents were transferredto LEK-AM as part of previous cooperation:1. Full CEP and EU ASMF documentation (open part) for the micronized substance, compliant with EMA and ICH requirements2. Confirmation of GMP compliance for production in the form of a GMP certificate for both the micronized active substance and its intermediates3. Written confirmation of GMP compliance (WC) according to Directive 2011/62/EC if manufactured outside Europe4. Stability studies for micronized batches (if not presented in the EU ASMF)5. Nitrosamine risk assessment report compliant with ICH and EMA requirements6. Elemental impurity risk assessment report compliant with ICH Q3D and EMA requirements |

1. Assessment

**The contracting authority will assess offers based on the following criteria:**

**- Micronized material, micronization process covered by CEP documentation**

* **Pc1 – Price – 80% of the score – unit net price – price per 1 kg**
* **Pc2 – Micronization –** 20% **–** if the micronized material is covered by CEP documentation – the offer receives 20 points. Otherwise, 0 points.
* The best offer will be the one that obtains the highest number of points according to the formula:

**Score = Pc1 + Pc2**

The number of points for the **Price** criterion is calculated using the formula::

$$P\_{C1}=\frac{C\_{N}}{C\_{B}}\*80\_{}$$

where:

|  |  |
| --- | --- |
| PC1 | * points awarded in the criterion
 |
| CN | * lowest net price among all evaluated offers
 |
| CB | * net price of the evaluated offer
 |

*Appendix no. 1 to the Market Insight Form*

**Information to be completed by the Offeror:**

**Estimated value of the order regarding the items described in detail in point II.**

Full name of the Contractor: ………………………

Contractor’s address: ………………………

Tax Identification Number [Numer Identyfikacji Podatkowej, NIP]: ………..…………………

Contact person: ………………………

Offer drafting date: ………………………

|  |
| --- |
| **VALUATION OF THE SUBJECT OF THE ORDER – Metformin Hydrochloride** |
| *Offered quantity (in kg)* | *Unit net cost (price per 1 kg)*  | Order execution time from placement (no longer than 3 months) | Is the material micronized and the process covered by CEP documentation (YES/NO) | Payment terms |
|  |  |  |  |  |

We declare that the quality of the offered subject of the order complies with the European Pharmacopoeia (Ph. Eur.), *Metformin Hydrochloride* monograph, and meets the requirements specified in point II.7 of the market research form.

I declare that the documents indicated in point 3.2 (detailed description of the subject of the order: additional requirements) have been delivered by the Contractor to Przedsiębiorstwo Farmaceutyczne LEK-AM sp. z o.o. as part of earlier cooperation YES/NO\*\*

\*\* If NO is selected, the complete documentation must be attached to the offer.

…………………………………… ..…….………………………………………

*Date and place Signature*